ADVENTRX Pharmaceuticals Adds Vice President of Clinical and Medical Affairs to Expand Clinical Trial Efforts
March 11 2004 - 10:05AM
PR Newswire (US)
ADVENTRX Pharmaceuticals Adds Vice President of Clinical and
Medical Affairs to Expand Clinical Trial Efforts SAN DIEGO, March
11 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.
(BULLETIN BOARD: AVRX) announced today that Cellia Habita, M.D.,
Ph.D., has joined its senior management team as Vice President,
Clinical and Medical Affairs. In this role, Dr. Habita will be
responsible for the Company's global clinical developments and
regulatory submissions. "Dr. Habita brings a breadth of product
development, clinical and regulatory experience to ADVENTRX," said
Nicholas Jon Virca, President & CEO of ADVENTRX. "In an
immediate effort to further the clinical development of our lead
cancer drug, CoFactor(TM), Dr. Habita will seek
regulatoryclearances in Europe to expand CoFactor testing for
metastatic colorectal cancer and to begin Phase II testing of
CoFactor for pancreatic cancer." Previously, Dr. Habita was
Director of Product Development and Preclinical for Immusol, Inc.,
a biopharmaceutical company involved in development of therapies
for cancer, viral diseases and certain dermatologic and ophthalmic
disorders. At Immusol, Dr. Habita directed all product formulation,
toxicology and pharmacology testing and oversaw offsite
manufacturing. Dr. Habita was responsible for all regulatory
submissions, in addition to assisting with clinical protocols and
trial design. Under her leadership, two drug candidates were
successfully launched into clinical trials. Previous to Immusol,
Dr. Habita was Assistant Project Scientist at the Center for
Molecular Genetics at the University of California, San Diego
(UCSD). While at UCSD, she developed an in vivo gene transfer model
in fetal tissue and neonates for metabolic disorders. Dr. Habita
earned a Ph.D. in Human Genetics, completed her graduate research
at Oxford University in the UK at The Wellcome Trust for Human
Genetics where she identified chromosomal regions involved in Type
I Diabetes. Dr. Habita received an MS in Biology and Genetics of
Aging from The University of Paris VII in Paris, France and an M.D.
in General Medicine from the National Institute of Medical Sciences
in Algiers, Algeria. Her clinical training covered Pediatric and
Adult Endocrinology, Obstetrics/Gynecology and Orthopedic Surgery
at The Saint Louis and Robert Debre Hospitals in Paris, France and
she has conducted Genetic studies for Diabetes and Aging and
Epidemiological studies in public health. ADVENTRX ADVENTRX
Pharmaceuticals Inc. is a biopharmaceutical research and
development company whose business strategy is to commercialize
leading edge medical research through licensing agreements with
prominent universities and research institutions. The Company
focuses its energy in cancer and antiviral research to launch
products that either extend the usefulness of current therapies or
replace marginal therapies with new approaches to treatment. This
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of thePrivate Securities
Litigation Reform Act of 1995. Such statements are made based on
management's current expectations and beliefs. Actual results may
vary from those currently anticipated based upon a number of
factors, including uncertainties inherentin the drug development
process, the timing and success of clinical trials, the validity of
research results, and the receipt of necessary approvals from the
United States Food and Drug Administration. The Company undertakes
no obligation to release publicly any revisions, which may be made
to reflect events or circumstances after the date hereof. Contact:
Investor Contact: Stephanie Carrington, The Ruth Group 646-536-7017
Media Contact: Cynthia Isaac, Ph.D., The Ruth Group 646-536-7028
DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Investors -
Stephanie Carrington, +1-646-536-7017; or Media - Cynthia Isaac,
Ph.D., +1-646-536-7028, both of The Ruth Group, for ADVENTRX
Pharmaceuticals, Inc.
Copyright